Late-Breaking Abstract Information and Eligibility
Late-breaking Abstract (LBA) submission is solely for abstracts with late-breaking data and not for abstracts submitted “late”. The Late-breaking Abstract deadline is not intended to be an extension of the general submission deadline. Late-breaking Abstracts highlight novel and practice-changing studies, and only apply to data that would have not otherwise have been presented as an abstract at the 38th Annual Meeting.
New in 2023: Late-breaking Abstracts (LBAs) no longer have an application requirement. LBAs do not need to submit an application or a place-holder abstract before the Regular/YIA Abstract deadline (June 27). Late-breaking Abstracts should be submitted during the LBA submission period, from July 10 – Sept. 6.
If a Late-breaking Abstract is not accepted, it will not be published or presented at the meeting. There is no longer an option for it to be considered as a Regular Abstract.
Examples of acceptable late-breaking abstracts include the following (in each case, results were not available or significant by the regular abstract submission deadline):
- Results of a practice-changing prospective Phase III clinical trial
- Phase II study showing anti-tumor activity in a novel context
- An early clinical trial with novel proof-of-principle data
- Demonstration of novel cancer biology with therapeutic implications
For late-breaking abstracts, authors need to justify why the abstract is considered late-breaking, for both clinical and laboratory-based studies.
The data in the abstract must not be published prior to SITC 2023.
Late-breaking Abstract Oral Presentation Opportunities
Late-breaking abstracts are considered for, but not limited to, oral abstract presentations during the Late-Breaking Abstract Sessions from 11:45 a.m.–12:15 p.m. on Friday, Nov. 3, 2023 and 11:25–11:55 a.m. on Saturday, Nov. 4, 2023.